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Opiate dependent Mothers and the use of naltrexone in pregnancy in Western Australia

Abstract
Objective: This paper will review and discuss the controversial use of naltrexone in
pregnancy in Western Australia, and whether it is a viable alternative to the methadone
maintenance therapy programme for pregnant opiate dependent mothers.
Design: There is an absence of sufficient evidence regarding naltrexone use in pregnancy due
to the limited range of human studies.
Setting: naltrexone implants are being used in Western Australia as a treatment for opioid
dependency, and although contraindicated for insertion during pregnancy there are a number
of women who conceive whilst already undergoing treatment.
Participants: Pregnant mothers have limited choices for treatment for opioid dependency
and withdrawal is contraindicated whilst pregnant.
Findings: A review of the available data reveals naltrexone is associated with improved
maternal and fetal outcomes.
Key conclusions: Extensive research into this area in the form of large, multi-centre trials is
required to confirm the results of the current research.
Keywords: naltrexone, pregnancy, methadone, opioid dependency.
Introduction
A basic exploration of the literature within the ‘CINAHL’ and ‘PUBMED’ databases on 20th
March 2012 and again on 1st May 2012, focusing specifically on articles published in the last
five to ten years; provided a limited amount of research specific to naltrexone implant use in
pregnancy; and revealed a minimal amount of literature on the use of naltrexone in
pregnancy. The aim of this discussion paper is to provide an insight into the latest research
regarding the controversial use of naltrexone in pregnancy for opiate dependent women; and
to explore whether naltrexone could be the optimal treatment programme for opioid
dependent pregnant mothers.
Opiate use in pregnancy
Throughout Australia, the rate of women using prescribed and illicit opiates is escalating
(Australian Institute for Health and Welfare (AIHW), 2010). A large proportion of these

women are of childbearing age and/or pregnant and dependent on opiates.
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Being dependent on a substance has been defined as a maladaptive pattern of substance use
(American Psychiatric Association (APA), 1994). This usually leads to clinically significant
impairment or distress (Mysels, Cheng, Nunes, & Sullivan, 2011). Altered physiological
states, due to the repeated administration of a drug, can lead to a specific syndrome of
withdrawal on cessation of that substance (Goradetzky, Sahakian, Robbins, & Ersche, 2010).
Tolerance to a particular drug or substance may also develop, whereby continued use of the
same amount of drug leads to a diminished effect, so that markedly increased amounts of the
substance are required to achieve similar effect level (Haile, Kosten, & Kosten, 2010).
Opioid use is prevalent in Australia, both from illicit use and abuse of prescribed opiates
which may have developed during medical treatment with opioid analgesics. In a recent
household survey, it was reported that 14.7% of the Australian population, aged over 14
years, had used illicit drugs within the last 12 months (Australian Institute of Health and
Welfare (AIHW), 2010). Recent illicit drug use amongst females was highest in the 20 – 29
year age group, at 24.3 % (AIHW, 2010). This same survey reported that 1 in 5 women were
drinking at levels that put them at risk of harm, which is more than two standard drinks a day
on average; and that the misuse of prescribed medication had risen to 4.2% (AIHW, 2010).
The age groups of the women reported on in this survey are within the central time-frame
period in a woman’s child-bearing years.
Withdrawal from opiates during pregnancy is not recommended due to risks to the fetus in
the form of increased risk of infant mortality and low birth weight for gestational age (Bell &
National Working Group, 2006), and the high risk of maternal relapse (Haile, Kosten &
Kosten, 2010).
The Methadone Maintenance Therapy (MMT) programme is the main prescribed therapy for
opiate dependence and is essentially a synthetic opioid (Salehi, Zargar & Ramezani, 2011);
which produces a slow, extended detoxification. Research suggests that methadone helps
those dependent on opiates to reduce or cease their opiate use (Mattick, Breen & Kimber,
2009). This is accomplished by retaining participants in treatment and decreasing heroin use
which appears to be better than treatments that do not utilise opioid replacement therapy
(Mattick, Breen & Kimber, 2009). Outcomes of the MMT programme include cessation of
intravenous drug use, improved physical health and nutrition, reduced criminal activity and
improved social supports (Judson, Bird, O’Conner, Bevin, Loan, Schroder et al, 2010).
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There are two other treatment options available for opiate dependency in Australia.
Buprenorphine is a partial opiate agonist (Wesson & Smith, 2010), which works by binding
the opiate receptor and exerting a mild opioid effect, whilst blocking other opiates from
binding the receptor. This relieves cravings but also reduces the opioid effects of any coadministered opioid (Sadock et al, 2009). Naltrexone is an opiate antagonist (Wesson &
Smith, 2010), which is a drug that binds a cell receptor without exerting a response, but
blocks the effect of another drug and thereby nullifies the effects of any co-administered
opiate (Sadock et al, 2009).
Medication safety in pregnancy is directed by national evidence-based guidelines produced
by the Australian Drug Evaluation Committee (ADEC). Each drug is categorised by taking
into account the known harmful effects on the fetus, including birth defects, harmful perinatal
effects and the potential to cause problems later in life (ADEC, 2011).
Opioid use in pregnancy has been associated with intrauterine growth restriction (IUGR);
pre-term birth, low birth weight, microcephaly, meconium staining of the amniotic fluid, fetal
death in-utero (FDIU) and the development of neonatal abstinence syndrome (NAS)
following birth (Jones, O’Grady, Johnson, Velez & Jansson, 2010). However, withdrawal
from opiates during pregnancy is not only dangerous for the fetus due to the associated fetal
distress (ref), increased infant mortality and low birth weight for gestational age, but also
carries a high risk of relapse for the mother. Therefore, pregnant women dependent on opiates
are usually offered MMT in the first instance (New South Wales Department of Health (NSW
DoH, 2006).
Methadone in pregnancy
Methadone is only legally available for use with a written prescription and enrolment on a
MMT programme; it does not cause fetal anomalies, however it may affect neurobehaviours
(Jansson, Di Pietro, Elko, Williams, Milio & Velez, 2011), and cause respiratory depression
in neonates or neonatal abstinence syndrome (NAS) in the newborn infant (McCarthy,
Leamon, Stenson, & Biles, 2008). Methadone has been associated with increased rates of
ante-partum haemorrhage, increased neonatal mortality and reduced birth weight, although
this is significantly lower than that associated with heroin use (Bell & Harvey- Dodds, 2008).
Despite these complications methadone is considered safer in pregnancy than heroin, and is
therefore recommended for use in pregnant women if opiate replacement is necessary
(Winklbaur, Kopf, Ebner, Jung, Thau, & Fischer, 2008).
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Women engaged on the MMT have birthed babies with improved fetal development and
reduced special care nursery admission (Cleary, Eogan, O’Connell, Fahey, Gallagher, Clarke,
et al, 2012). This has been achieved by increasing infant birth weight and reducing the
perinatal and infant mortality rate; however the protective effects are reduced by concomitant
heroin use. Furthermore, withdrawal from methadone is associated with a high risk of relapse
to heroin use, and should not be encouraged during pregnancy (Bell & Harvey-Dodds, 2008).
Whilst the MMT has long been established as first line therapy for opiate dependency, it is
not without its disadvantages. Short term complications include: opportunity for concomitant
heroin use, drug diversion and an increased mortality rate during induction onto MMT due to
fatal overdose (Tait, Ngo, & Hulse, 2007; Ngo, Tait & Hulse, 2008). The long-term
disadvantages of methadone are that the patient remains opiate-dependent and therefore
retains many of the associated physical, mental, emotional and social effects of drug
dependence (Hulse, O’Neill, & Arnold-Reed, 2004).
Naltrexone
An alternative approach to MMT is naltrexone, a drug that enforces opiate abstinence (Haile,
Kosten & Kosten, 2010). Naltrexone is a long-acting opioid antagonist that has been
registered for general use in the community since 1984 (Fram, Marmo & Holden, 1989). In
Australia, naltrexone is primarily registered for use in the treatment of alcoholism note it is
not licensed for this purpose in the United Kingdom) (BNF, 2011); however it may also be
used in opiate dependents, to help maintain abstinence from opioids by decreasing cravings
and blocking the effects of opiates via competitive inhibition (Sadock, Sadock & Kaplan,
2005).
A single 50mg naltrexone tablet provides protection against heroin overdose and blocks the
euphoric effects of heroin for 24 hours, and has been shown to be safe and effective (Farid,
McCallum, Tait, Dunlop & Hulse, 2009). The main issue limiting the utility of naltrexone has
proved to be compliance, as the dependent must remain motivated to administer the drug
daily (Ngo, Tait & Hulse, 2008; Hulse, Morris, Arnold-Reed & Tait, 2009). A related issue is
the loss of tolerance to opioids that develops whilst on naltrexone, such that if the dependant
ceases the medications and relapses back to heroin, they are at high risk of opiate overdose
Jones et al, 2012). Naltrexone implants remove the onus on the dependent to self-administer
the drug each day and leads to improved dependent outcomes and reduces the risk of
accidental overdose (Lobmaier, Kunoe, Gossop, & Waal, 2010). Naltrexone implants are a
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sustained-release preparation that maintains therapeutic blood levels for extended periods
(Tait, Ngo & Hulse, 2007). Although a Western Australian-based obstetrician has pioneered a
naltrexone implant that appears to satisfy the above criteria, objections to its widespread use
remain strong and the use of this product has become highly controversial (Lobmaier,
Gossop, Waal & Bramness, 2010). At present it may be administered only under the
restrictions of a clinical trial, and research into its safety and efficacy continue (Wodak, Ali,
Henry & Sansom, 2008).

The use of Naltrexone in pregnancy
Naltrexone implants have not been approved for use in pregnancy in Australia (The National
Health and Medical Research Council (NHMRC). No increase in malformations or harmful
effects has been observed in the use of naltrexone implants, conducted amongst a limited
number of pregnant women (Hulse & O’Neill, 2002). However animal studies have shown
changes offspring behaviour, neuroanatomy and biochemistry (Farid, Dunlop, Tait & Hulse,
2008). The paucity of conducted research suggests that in-utero exposure to naltrexone in rats
caused increased birth weight, which is possibly caused by the blocking of the growthsuppressing effects of endogenous opioids (Farid et al, 2009).
The NHMRC and the National Clinical Guidelines both advocate that the safety and efficacy
of naltrexone in pregnancy has not yet been established; therefore naltrexone should not be
offered in pregnancy except in the context of clinical trials. Currently, in Western Australia,
women who conceive whilst undergoing treatment with a naltrexone implant continue with
their pregnancies on the understanding that the safety of naltrexone in pregnancy is not
established and women are provided with informed consent (Hulse et al, 2003; Wodak et al,
2008). Babies born to mothers with naltrexone implants are usually referred for paediatric
review following birth as a precautionary measure.
As pregnancy remains a contraindication with the use of naltrexone implants, women are not
encouraged to conceive, however a number of women after receiving the implant have
inadvertently conceived a child. From the limited research available, the neonate and
obstetric outcomes have been unremarkable (Hulse, O’Neill &Arnold-Reed, 2004; Jones et
al, 2012), and women have remained opiate free during the pregnancy. Prior to the implants,
the women had been unstable on oral naltrexone, with multiple relapses back into intravenous
5

heroin use. Notably, there is no neonatal abstinence syndrome associated with the use of
naltrexone, in contrast to that of MMT (Jansson et al, 2011).
A recent review of naltrexone in pregnancy (Jones, Chisolm, Jansson & Terplan, 2012),
highlighted a number of pregnancy-specific issues. These included: variable adverse effect
profiles related to timing of first use; potential drug interactions during labour leading to
difficulty in providing effective analgesia, limited data of the effects on the breastfeeding
infant, and the ethical difficulties in including pregnant women in clinical trials. Yet given
that the date currently available suggests no increased risk for poor outcomes related to
antenatal naltrexone exposure, the study supported our own conclusion that further research
into this area would greatly benefit clinicians in the field.
Conclusion
In contrast to the methadone maintenance therapy, the approved treatment programme for
pregnant opiate dependent women, naltrexone offers an opportunity to remain opiate-free
throughout pregnancy. A review of the available data reveals naltrexone is associated with
improved maternal and fetal outcomes - seemingly without any ill effects. However,
extensive research into this area in the form of large, multi-centre trials is required to confirm
the results of the current research, specifically comparing maternal and fetal outcomes with
the use of either MMT or naltrexone.
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